---
title: "Maccura released its performance for the first three quarters, with a net profit attributable to the parent company of 37.1034 million yuan, a decrease of 86.81%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/262626402.md"
description: "Maccura released its third-quarter report for 2025, with operating revenue for the first three quarters amounting to 1.608 billion yuan, a year-on-year decrease of 17.44%. The net profit attributable to the parent company was 37.1034 million yuan, a year-on-year decline of 86.81%; the net profit after deducting non-recurring gains and losses was 64.3071 million yuan, a year-on-year decrease of 77.95%. The basic earnings per share were 0.0606 yuan"
datetime: "2025-10-24T12:19:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/262626402.md)
  - [en](https://longbridge.com/en/news/262626402.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/262626402.md)
generator: "portal-rs"
---

# Maccura released its performance for the first three quarters, with a net profit attributable to the parent company of 37.1034 million yuan, a decrease of 86.81%

According to the Zhitong Finance APP, Maccura (300463.SZ) released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 1.608 billion yuan, a year-on-year decrease of 17.44%. The net profit attributable to shareholders of the listed company was 37.1034 million yuan, a year-on-year decrease of 86.81%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 64.3071 million yuan, a year-on-year decrease of 77.95%. The basic earnings per share were 0.0606 yuan

### Related Stocks

- [300463.CN](https://longbridge.com/en/quote/300463.CN.md)

## Related News & Research

- [11:00 ETCovationBio's Xatryx® Mass Production On Spec, to Debut First Non‑Food Bio‑Based Athletic Insole at NW Materials Show in the U.S.](https://longbridge.com/en/news/297804526.md)
- [Independent Oil & Resources H1 net profit rises 0.74% to NOK 25.8 million](https://longbridge.com/en/news/297475302.md)
- [PharmaEssentia’s Besremi receives FDA approval for ET](https://longbridge.com/en/news/297630746.md)
- [Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President](https://longbridge.com/en/news/297630906.md)
- [00:01 ETNorth Carolina Approves Reimbursement of VR Therapy for Neurodivergent Residents Under NC Innovations Waiver](https://longbridge.com/en/news/297593314.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**